Tachyon Therapeutics, a clinical-stage biotechnology company, raised USD 11.6 million via an equity funding round, with the investors including Veblen Ventures, Khosla Ventures, Red Tree Venture Capital, and other existing investors. This brings the total funds raised to USD 18.7 million, including USD 7.1 million in grant funding. 

The new funds will be used to conduct phase 1 clinical trials of TACH 101, a small molecule KDM4 histone demethylase inhibitor, for advanced solid tumors. In addition, the funds will be used to progress the company’s lineup of novel oncology drugs, candidates which are aimed at previously unexamined mechanisms of tumor formation. 

California-based Tachyon Therapeutics is a biotechnology company focused on developing small-molecule drugs for the treatment of cancer. The company’s research is centered on identifying and targeting novel mechanisms of tumorigenesis, which are the processes that lead to the formation and growth of tumors. The company’s lead drug candidate, TACH 101, is a first-class KDM4 histone demethylase inhibitor that is currently undergoing clinical trials for the treatment of advanced solid tumors.